Victory Capital Management Inc. lessened its holdings in Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) by 22.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 759,802 shares of the biopharmaceutical company’s stock after selling 221,137 shares during the quarter. Victory Capital Management Inc. owned 0.78% of Fate Therapeutics worth $7,624,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in FATE. Quantbot Technologies LP acquired a new stake in Fate Therapeutics in the third quarter worth about $69,000. Great West Life Assurance Co. Can acquired a new stake in shares of Fate Therapeutics during the third quarter worth about $91,000. Royal Bank of Canada lifted its holdings in shares of Fate Therapeutics by 13.8% during the third quarter. Royal Bank of Canada now owns 4,575 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 556 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Fate Therapeutics by 14.4% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,649 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 1,597 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Fate Therapeutics by 47.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,660 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 4,685 shares during the period.
Fate Therapeutics Price Performance
Fate Therapeutics stock opened at $5.04 on Friday. The stock has a market capitalization of $495.84 million, a PE ratio of -2.08 and a beta of 1.49. Fate Therapeutics, Inc. has a 12 month low of $4.02 and a 12 month high of $37.13. The business has a 50 day simple moving average of $5.63 and a 200-day simple moving average of $9.08.
Insider Buying and Selling
In other news, Director Redmile Group, Llc purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, April 20th. The stock was purchased at an average cost of $5.99 per share, for a total transaction of $119,800.00. Following the completion of the transaction, the director now owns 12,879,119 shares of the company’s stock, valued at $77,145,922.81. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.04% of the stock is owned by company insiders.
Analysts Set New Price Targets
A number of equities research analysts recently commented on FATE shares. StockNews.com started coverage on Fate Therapeutics in a report on Thursday, May 18th. They set a “hold” rating for the company. Cantor Fitzgerald decreased their target price on Fate Therapeutics from $8.00 to $5.00 in a report on Thursday, May 4th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $6.00 target price on shares of Fate Therapeutics in a report on Monday, March 27th. Piper Sandler decreased their price target on Fate Therapeutics from $12.00 to $7.00 in a report on Wednesday, March 1st. Finally, EF Hutton Acquisition Co. I reissued a “buy” rating and issued a $10.00 price target on shares of Fate Therapeutics in a report on Wednesday, March 1st. Two equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $16.24.
Fate Therapeutics Profile
Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D.
- Get a free copy of the StockNews.com research report on Fate Therapeutics (FATE)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.